AstraZeneca and Eccogene revealed promising trial data on ECC5004, an oral GLP-1 receptor agonist for obesity, showing safety, tolerability, and convenient dosing.
AstraZeneca Unveils Early Data From Chinese-Firm Partnered Oral Weight Loss Drug
Where Today's News Shapes Tomorrow
